The abstract is read at the publisher; the summary is JClub's.
In 24 individuals with type 2 diabetes, dapagliflozin (10 mg/day) for 6 months does not change LDL-ApoB100 fractional catabolism (0.88 ± 0.37 vs 0.79 ± 0.31 pool/day; p=0.16).
- Why it matters: SGLT2 inhibitors reduce atherosclerosis, but their impact on human ApoB-containing lipoprotein metabolism is unclear, including whether they impair LDL catabolism via LDL receptor effects.
- What they did: In a parallel double-blinded in vivo stable-isotope kinetic study using tri-deuterated [2H3]-labelled L-leucine, participants received dapagliflozin or placebo and were assessed before and after 6 months.
- The result: Dapagliflozin did not significantly alter plasma triglyceride, LDL-cholesterol, ApoB100, LDL-ApoB100 pool, or production rate, but it reduced direct VLDL1-ApoB100 catabolism (p=0.001) and increased indirect VLDL1→VLDL2/IDL and VLDL2→IDL catabolism (p=0.001 and p=0.049), with no significant side-effects.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.